- Details
- Hits: 395
October 24, 2025
As jurisdictions worldwide continue to legalise cannabis for both “medicinal” and recreational use, a disturbing pattern has emerged on our roads. Recent data from Ohio revealing that over 40% of drivers killed in car crashes tested positive for THC represents just the latest confirmation of what extensive research has been warning us about for years: cannabis-impaired driving has become a critical public safety issue that demands immediate attention.
The Scope of the Problem
The Ohio findings are far from an isolated incident. A 2022 study from the National Highway Traffic Safety Administration found that more than 25% of all those killed or seriously injured in road accidents who tested positive for any drug tested positive for marijuana, a higher rate than that found for alcohol at 23%. Even more alarming, a September 2024 study by researchers at London School of Economics found that the legalisation of recreational marijuana increased traffic fatalities by 75% in Alaska, 18% in California, 16% in Oregon, and 15% in Colorado.
The implications are staggering. Analysis from Harvard and New York Medical College researchers shows that if marijuana were legalised nationwide, the U.S. would suffer an additional 6,800 fatal crashes per year. These numbers represent real lives lost, families devastated, and communities forever changed by preventable tragedies.
Direct Impairment of Critical Driving Skills
Cannabis consumption significantly impairs multiple cognitive and motor functions essential for safe driving. Research has consistently demonstrated that marijuana use affects motor control and reaction time, with studies showing marijuana increases driver reaction time and the number of incorrect responses to emergencies. Users demonstrate difficulty maintaining consistent lane position and experience problems with speed variability. The ability to process multiple inputs simultaneously becomes compromised, affecting divided attention and attention maintenance capabilities that drivers rely upon constantly.
Executive function deteriorates under the influence of THC, affecting route planning and judgment in ways that can have fatal consequences. Perhaps most concerning, recent research reveals that cannabis has significant adverse effects on visual acuity, contrast sensitivity, stereoacuity, and causes night-vision disturbances. Laboratory studies examining the impairment effects of marijuana use on psychomotor and cognitive functions have shown that cannabis consumption can impair driving task-related abilities such as motor control, executive function, visual processing, short-term memory, and working memory in a dose-dependent fashion.
Reviews of studies on the effects of marijuana on driving skills have demonstrated that marijuana specifically impairs certain skills necessary for safe driving. These include controlling speed variability, maintaining proper lane positioning, sustaining adequate reaction time, managing divided attention, maintaining attention over time, planning routes effectively, making sound decisions, and properly assessing risks. In some driving simulator studies, marijuana use increased driver reaction time and the number of incorrect responses to emergencies. Drivers crashed more frequently into sudden obstacles when on high doses of THC, though this effect was not observed at lower doses.
Demonstrable Increase in Crash Risk
The crash risk data leaves no doubt. Multiple studies have shown that marijuana use increases the risk of fatal crash involvement, with drivers facing injury risk between 1.8 and 2.8 times higher than non-users. Research on drivers in fatal crashes has shown that THC-positive drivers were more than twice as likely to crash as drivers without THC in their system. The odds of drivers being found responsible for a crash increase substantially with rising marijuana concentrations in the blood.
At very high THC levels, the odds ratio for crashes can reach 10.0, representing an extraordinarily elevated risk. Studies investigating cannabis use as a risk factor for motor vehicle crash fatalities have found that while the degree of impairment varies by tetrahydrocannabinol level, the association between cannabis use and significantly increased risk of fatal crash involvement remains consistent across research. Meta-analyses confirm that acute THC administration impairs aspects of driving performance in measurable and significant ways.
The results are devastating
Dangerous THC Concentration Levels
The Ohio data revealed extremely high THC levels among deceased drivers, averaging 30.7 ng/ml. Impairment thresholds typically fall around 2-5 ng/ml, meaning these drivers had concentrations more than six times higher than levels associated with significant impairment. These elevated concentrations indicate recent use before driving and demonstrate a complete disregard for impairment risks. The data suggest an absence of effective deterrence or awareness and point to a potential normalisation of drugged driving behaviour that should alarm anyone concerned with public safety.
Colorado’s Department of Public Health and Environment examined driving impairment and motor vehicle crash risk relative to marijuana use, and evidence indicating how long it takes for impairment to resolve after marijuana use. Their findings confirmed that the risk of a motor vehicle crash increases among drivers with recent marijuana use. Using alcohol and marijuana together increases impairment and the risk of a motor vehicle crash more than using either substance alone. For less-than-weekly marijuana users, using marijuana containing 10 milligrams or more of THC is likely to impair the ability to safely drive, bike, or perform other safety-sensitive activities.
The Post-Legalisation Effect
Evidence from jurisdictions with experience in cannabis legalisation tells a cautionary tale that policymakers ignore at their peril. In Washington State, researchers assessed cannabis involvement and THC levels among fatally injured drivers before and after legalising non-medical cannabis use. Using data from all motor vehicle crash decedent drivers based on observed and imputed values, the prevalence of cannabis involvement in fatalities was 9% prior to legalisation and 19% after. In adjusted analyses, the proportion of decedent drivers with high THC levels (greater than 10 ng/ml) increased nearly five-fold after legalisation.
Although cannabis testing rates increased during the study period, findings remained generally similar when restricted to those with completed cannabis testing. This study was one of the first to impute cannabis involvement in motor vehicle crash fatalities among decedents without testing and to measure and impute THC levels rather than simply the presence or absence of THC. The results add to literature suggesting that legalising cannabis may increase motor vehicle crash fatalities and highlight the need to better characterise and mitigate those risks.
Colorado’s experience has been similarly troubling. The state’s Division of Criminal Justice analysed driving under the influence case filings and found that among cases with cannabinoid screens, 66% tested positive for cannabinoids, with 57% of all screened cases testing positive for Delta 9-THC specifically. The median value of Delta 9-THC among individuals screened was 5.2 ng/mL and the mean was 8.2 ng/mL, both of which exceeded the permissible inference level. About half of the case filings with Delta 9-THC confirmation tests had levels at or above the permissible inference level of 5 ng/mL.
The Myth of Compensatory Behavior
While some studies have suggested that marijuana users may adopt compensatory behaviours like driving slower or maintaining greater following distances, this finding creates a misleading impression of safety. Simulator studies investigating behavioural changes when driving under the influence of marijuana have concluded that marijuana use by drivers may cause decreased speeds, fewer attempts to overtake, and increased following distance to the vehicle in front. These findings stand in sharp contrast to studies investigating the effects of alcohol use.
However, these behaviours do not eliminate the fundamental impairment caused by cannabis use. They merely reflect user awareness of diminished capacity. Recent research shows that users’ perception of when impairment has resolved often occurs before actual driving performance improves. One study measuring driver performance in a simulator showed subjects perceived the impairing effects of THC to be eliminated before a measurable improvement in driving performance was seen. The false sense of security created by perceived compensation can itself be dangerous, as drivers may believe they are driving safely when objective measures show continued impairment.
Furthermore, compensatory behaviours do not prevent the fundamental cognitive and motor impairments that increase crash risk. Studies have shown that despite potentially driving more slowly, marijuana-impaired drivers still hit more pedestrians, exceed speed limits more often, make fewer stops at red lights, and make more centreline crossings than sober drivers. The notion that slower driving compensates for impairment ignores the reality that safe driving requires far more than speed control.
The Myth of Tolerance
Cannabis advocates often claim that regular users develop tolerance to impairing effects, making them safer drivers than occasional users. Evidence strongly contradicts this. While some tolerance to THC’s effects may develop, it does not eliminate impairment or reduce crash risk. In reality, as tolerance builds, users tend to increase their dose to reach the same psychoactive effects—a pattern well documented in both research and clinical settings. This makes the supposed safety benefit of tolerance an illusion, as users simply consume more to overcome reduced sensitivity. Studies comparing occasional and daily cannabis users found that both groups showed significant driving impairment. Although daily users drove slower, this compensatory behaviour failed to remove measurable performance deficits.
Chronic Impairment and False Comparisons
Regular users may also experience chronic impairment due to THC’s fat-soluble nature, which allows it to linger in brain tissue. The body continues to release and metabolise this residual THC, sometimes converting it into 11-hydroxy-THC—an even more intoxicating compound. This ongoing effect undermines claims that frequent users are safer. Similar arguments were once made about alcohol tolerance, with drinkers claiming experience made them safer drivers. Society rightly rejected that logic when setting drunk driving laws. The same principle applies to cannabis: impairment remains impairment, regardless of tolerance, and driving under its influence poses an unacceptable risk (Source: WRD News)
- Details
- Hits: 456
New research reveals a stark warning for cannabis users: marijuana significantly increases the risk of dangerous heart rhythm problems that can prove fatal.
A large-scale study published in August 2025 by researchers from the University of California, Georgetown University, and multiple other medical institutions found that cannabis use substantially raises the likelihood of developing serious cardiac arrhythmias. The findings show cannabis users face more than triple the risk of ventricular tachycardia and ventricular fibrillation compared to non-users.
Understanding the Risk
The retrospective study analysed electronic health records from 68 U.S. healthcare organizations, examining over 210,000 cannabis users matched with a similar number of control subjects. Researchers found 97 cases of ventricular tachycardia or fibrillation among cannabis users versus only 35 cases in the control group, representing a hazard ratio of 3.078.
Ventricular arrhythmias represent the most severe type of irregular heartbeat. These conditions occur when the heart’s lower chambers beat too quickly or chaotically, potentially preventing the heart from pumping blood effectively. Without immediate treatment, ventricular fibrillation can cause sudden cardiac death within minutes.
Beyond Ventricular Arrhythmias
The study documented elevated risks across multiple types of heart rhythm disorders. Cannabis users showed 1,895 cases of atrial fibrillation or flutter compared to 1,332 in the control group, with a 55% increased risk. Paroxysmal tachycardia occurred in 1,065 cannabis users versus 672 controls, representing a 79% increased risk, while premature beats affected 1,135 cannabis users compared to 745 controls, a 74% increase.
Atrial fibrillation emerged as the most common arrhythmia among cannabis users, though less immediately dangerous than ventricular arrhythmias. Atrial fibrillation still carries serious consequences, including increased stroke risk and heart failure.
Why Cannabis Affects Heart Rhythm
Multiple mechanisms may explain how cannabis triggers arrhythmias, including THC’s ability to block cardiac ion channels and prolong the QT interval. THC also enhances sympathetic nervous system activity through CB1 receptor activation, increasing heart rate and susceptibility to irregular rhythms.
Cannabis can cause coronary vasospasm and endothelial dysfunction, creating conditions that promote arrhythmias. Chronic use may lead to cardiac inflammation and fibrosis, causing atrial remodelling directly linked to atrial fibrillation development.
Research suggests the highest risk period occurs within one to two hours after cannabis use, indicating acute exposure poses immediate danger.
A Growing Public Health Concern
As cannabis legalization expands, hospitalization rates for cannabis-related arrhythmias have increased 31% over the past decade. The rise in arrhythmia-related hospitalizations appears particularly pronounced among teenage cannabis users.
Cannabis-induced arrhythmias disproportionately affect young, otherwise healthy individuals without structural heart disease, challenging assumptions that heart rhythm problems primarily afflict older adults with existing cardiovascular conditions.
The study used propensity score matching to ensure fair comparison between groups, accounting for age, sex, cardiovascular risk factors, and medication use. This rigorous methodology strengthens confidence in the findings.
What This Means for Users
Healthcare providers should counsel patients about cardiovascular risks associated with cannabis, particularly those with pre-existing heart conditions. The cardiovascular effects of marijuana deserve serious consideration as legal access continues expanding nationwide.
For individuals using or considering cannabis, these findings provide important context. Heart arrhythmias represent serious medical emergencies requiring immediate attention. Anyone experiencing symptoms like rapid heartbeat, chest pain, dizziness, or fainting should seek medical care promptly.
The research adds to mounting evidence documenting adverse cardiovascular effects of cannabis use. As the scientific community continues investigating these risks, current data already provide clear cause for concern about marijuana’s impact on heart health.
Source (WRD News)
- Details
- Hits: 717
(An Ed Sheeran moment!)
The Turning Point: In a revealing poem featured in the collection, Matthew McConaughey describes how cannabis evolved from recreational enjoyment into something far more problematic. Matthew McConaughey quitting cannabis represents a significant shift in his personal journey. He recounts the contrast between earlier experiences with the drug and its deteriorating effects over time.
McConaughey explains that what began as casual cannabis use became increasingly detrimental to his functioning. Rather than providing inspiration, the substance began causing paralysis and obsessive overthinking. He describes finding himself fixated on trivial details for extended periods, convinced they held significance when they did not.
A Catalyst for Change: A particularly striking moment prompted his reassessment of cannabis dependence. Matthew McConaughey reveals that on one occasion, he became so engrossed in listening to music whilst under the influence that he missed his own birthday celebration entirely. This incident underscored how cannabis had begun interfering with his ability to engage meaningfully with life. (Full Story WRD News)
- Details
- Hits: 448
Mounting scientific evidence continues to challenge the narrative that cannabis is a harmless substance, with alarming new research demonstrating significant THC effects on fertility and embryonic development.
A groundbreaking study conducted by researchers in Canada and Israel has uncovered disturbing links between THC exposure and chromosomal abnormalities in human embryos created through IVF. The findings add to growing concerns about the drug’s impact on reproductive health at a time when cannabis use amongst pregnant women is reportedly increasing.
Chromosomal Chaos
The research team’s analysis revealed that embryos exposed to THC experienced widespread genetic disruption. When comparing treated embryos to controls, scientists identified 89 genes that became overactive and 227 genes that became suppressed—clear evidence of substantial biochemical interference.
Higher THC concentrations proved even more damaging, with 402 genes showing increased activity and 62 displaying reduced function. These dramatic shifts in genetic expression suggest that the cannabis impact on reproduction extends deep into cellular processes critical for healthy development.
Perhaps most concerning, the study documented a 9% increase in aneuploidy—a condition where embryos possess an incorrect number of chromosomes. This abnormality frequently prevents successful conception or leads to developmental problems. The research also found that THC exposure elevated the likelihood of complex aneuploidy, involving the gain or loss of multiple chromosomes simultaneously.
Male Fertility Under Threat
These findings complement well-established research demonstrating THC effects on fertility in men. A comprehensive 2019 systematic review examined chronic cannabis users and found striking correlations between consumption frequency and sperm quality.
Men smoking cannabis 10 or more times weekly showed significantly lower sperm counts compared to those using it 5 to 9 times per week, suggesting a dose-dependent relationship. A Danish study involving 1,215 participants reinforced these conclusions, revealing that weekly cannabis users had 28% lower sperm concentration and 29% lower total sperm count than non-users.
Epigenetic Concerns Mount
This summer, researchers uncovered evidence that cannabis use can permanently alter DNA expression through methylation—the addition of methyl groups to DNA molecules. This process can affect how genes function without changing the underlying genetic code itself, potentially passing consequences to future generations.
The cannabis impact on reproduction now appears to operate through multiple mechanisms, from direct chromosomal damage to epigenetic modifications that may have long-lasting effects.
Vulnerable Populations at Risk
The Wall Street Journal recently highlighted a troubling trend: increasing numbers of pregnant women turning to marijuana to manage pain and anxiety. Ironically, robust scientific data indicates that cannabis actually exacerbates both conditions rather than alleviating them.
This disconnect between perception and reality reflects the success of industry marketing efforts that have positioned cannabis as a natural, safe alternative to conventional treatments. The consequences of this messaging are now becoming apparent, with expectant mothers potentially exposing their developing babies to significant harm.
A Growing Body of Evidence
The latest research on THC effects on fertility represents just one piece of an increasingly worrying puzzle. Scientific studies have now documented cannabis-related harm across multiple organ systems, including the brain, heart, lungs, and the genetic mechanisms that control cellular function.
The cumulative evidence paints a picture starkly different from the “safe and natural” image promoted by commercial interests. For couples planning to conceive, individuals undergoing fertility treatment, and pregnant women, the message from science is becoming unmistakably clear: cannabis poses serious risks to reproductive health and embryonic development.
The Path Forward
As cannabis legalisation expands across various jurisdictions, the importance of evidence-based public health messaging has never been greater. The recent findings regarding the cannabis impact on reproduction underscore the urgent need for comprehensive education about the drug’s genuine risks, particularly for those of reproductive age.
Healthcare providers working with patients considering pregnancy or undergoing fertility treatment must be equipped with current research to offer informed guidance. The romantic notion of cannabis as a benign natural remedy simply cannot withstand scientific scrutiny, especially when the health of future generations hangs in the balance.
The latest study examining THC effects on fertility serves as a stark reminder that what we put into our bodies can have profound consequences—not just for ourselves, but for the children we hope to bring into the world.
Source: The Drug Report
- Details
- Hits: 449
Interest in the use of cannabis and cannabinoids to treat chronic non-cancer pain is increasing, because of their potential to reduce opioid dose requirements. We aimed to investigate cannabis use in people living with chronic non-cancer pain who had been prescribed opioids, including their reasons for use and perceived effectiveness of cannabis; associations between amount of cannabis use and pain, mental health, and opioid use; the effect of cannabis use on pain severity and interference over time; and potential opioid-sparing effects of cannabis.
Findings: 1514 participants completed the baseline interview and were included in the study from Aug 20, 2012, to April 14, 2014. Cannabis use was common, and by 4-year follow-up, 295 (24%) participants had used cannabis for pain. Interest in using cannabis for pain increased from 364 (33%) participants (at baseline) to 723 (60%) participants (at 4 years). At 4-year follow-up, compared with people with no cannabis use, we found that participants who used cannabis had a greater pain severity score (risk ratio 1·14, 95% CI 1·01–1·29, for less frequent cannabis use; and 1·17, 1·03–1·32, for daily or near-daily cannabis use), greater pain interference score (1·21, 1·09–1·35; and 1·14, 1·03–1·26), lower pain self-efficacy scores (0·97, 0·96–1·00; and 0·98, 0·96–1·00), and greater generalised anxiety disorder severity scores (1·07, 1·03–1·12; and 1·10, 1·06–1·15). We found no evidence of a temporal relationship between cannabis use and pain severity or pain interference, and no evidence that cannabis use reduced prescribed opioid use or increased rates of opioid discontinuation.
Interpretation: Cannabis use was common in people with chronic non-cancer pain who had been prescribed opioids, but we found no evidence that cannabis use improved patient outcomes. People who used cannabis had greater pain and lower self-efficacy in managing pain, and there was no evidence that cannabis use reduced pain severity or interference or exerted an opioid-sparing effect. As cannabis use for medicinal purposes increases globally, it is important that large well designed clinical trials, which include people with complex comorbidities, are conducted to determine the efficacy of cannabis for chronic non-cancer pain.
(Source: The Lancet – Public Health https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(18)30110-5/fulltext)
Also see